Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 3

2(28.6%)

N/A

1(14.3%)

Phase 4

1(14.3%)

7Total

Phase 2(3)

Phase 3(2)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT00261976Completed

A Long-term Safety Study of Infliximab (Remicade)

Role: collaborator

NCT00207714Phase 2Completed

An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis

Role: collaborator

NCT00207740Phase 2Completed

A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma

Role: collaborator

NCT00207727Phase 2Completed

A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis

Role: collaborator

NCT00207675Phase 3Completed

A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease

Role: collaborator

NCT00207701Phase 3Completed

A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.

Role: collaborator

NCT00237419Not ApplicableUnknown

Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis

Role: collaborator

NCT00554710Phase 4Completed

Top Down Versus Step Up Strategies in Crohn's Disease

Role: collaborator

All 8 trials loaded